ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Cash paid for IPR&D and development milestones by Year
Cash paid for IPR&D and development milestones ($M) ($M)
Eli Lilly Cash paid for IPR&D and development milestones: $3,008M in FY2025, down 10.1% from a year earlier.
Latest, FY2025
3,008
Period ended Dec 31, 2025
Change on a year earlier
-10.1%
3,346 in FY2024
History
8 years
Since FY2016
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Cash Flows.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cash paid for IPR&D and development milestones ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,008 | -10.1% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 3,346 | -15.2% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 3,944 | +248.7% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 1,131 | +69.2% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 669 | – | Form 10-K (filed 2024-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 1,808 | +66.3% | Form 10-K (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 1,087 | +1,876.0% | Form 10-K (filed 2019-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 55 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cash paid for IPR&D and development milestones ($M), annual FY2016–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/iprd-cash-paid
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.